VELCADE^® is the first oncology drug marketed and promoted by Millennium. The rapid clinical development of VELCADE—with FDA approval granted little more than four and a half years after initiation of the first clinical trial—reflects our intense commitment to novel treatments for cancer patients. To discover and develop such treatments, we focus on understanding key molecular pathways that play crucial roles in underlying disease processes, and on identifying therapeutically significant differences that may exist between people. We apply this approach broadly throughout our R&D program, to develop novel treatments not just for cancer but also for a number of other important diseases.

For more information about VELCADE, please go to the appropriate section of this website by selecting one of the links below, or call 1-866-VELCADE (US residents only).

VELCADE is being co-developed by Millennium Pharmaceuticals, Inc. and Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Millennium is responsible for commercialization of VELCADE in the U.S. Ortho Biotech Products, L.P. and the Janssen-Cilag group of companies are responsible for commercialization in the EU and the rest of the world. Janssen Pharmaceutical K.K. is responsible for commercialization in Japan.